Skip to Content
scroll

Imugene (IMU)

ASX.IMU $0.09

20 MINUTE DELAYED

14 DAYS FREE ACCESS

Join Market Matters and get full access
to all our Opinion + Action

LEARN MORE

IMU $0.09

20 MINUTE DELAYED

TODAY

0.00 %

1 YEAR RETURN

0.00%

VOLUME

0

DIV YIELD

0%

PE RATIO

0.00

52 WEEK RANGE

0.04

0.15

ANALYSIS

i

SHARE PRICE ACTIVITY
Last (Price)

0.09

Change

0.00 (0.00)

Bid / Ask

0.09 - 0.09

Volume

0

Turnover

0

Open

0.00

Day Range

0.09 - 0.10

VWAP

0.00

Prev Close

0.09

Last Trade

16/04 8:17am (AEST)

i

KEY INFORMATION
Sector

Healthcare

Shares Issued

6,265,953,280

NTA/Share

0.00

Last Dividend

0.00

Dividend Ex Date

0

Dividend Pay Date

29 MAR 2006

i

BROKER CALLS

current

Mean

2.00

Target Price

0.00

BUY

i

CURRENT ()
Revenue

0.00

EBITDA

-38.82

Profit

-39.17

Earnings Per Share (EPS)

0

Dividend Per Share (DPS)

0

Yield %

0.00

Market Cap

0

Price to Earnings Ratio (P/E)

0

i

TARGET PRICE FORECAST

i

ESTIMATES ()
Revenue

2.93

EBITDA

-41.20

Profit

-92.51

Earnings Per Share (EPS)

-0.02

Dividend Per Share (DPS)

0.00

i

BROKER CONSENSUS RECOMMENDATION

BUY

SELL

Target Price

0.00

Lt Growth Rate

0.00

Recommendation (BUY)

2.00
OPINION
ACTION
image description

Business Summary

Imugene Limited is an Australia-based clinical-stage immuno-oncology company. The Company is engaged in developing a range of new immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies, such as CAR T’s for solid tumors. Its PD-1 B-cell immunotherapy (PD1-Vaxx), aims to induce the body to produce polyclonal antibodies that block PD-1 signaling, and thus produce an anticancer effect. Its HER-Vaxx is a B-cell activating cancer immunotherapy designed to treat tumors that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. Its clinical trial candidates include VAXINIA (CF33 + hNIS), CHECKvacc (CF33 + hNIS + PD-L1), B-Vaxx and others.

image description

Relevant suggested news and content from the site

image description

Only available to Members

Take a free 14 day Market Matters trial – full access to all our reports, portfolios, positions, buy and sell recommendations. Access the latest views on the latest developments from professional money managers. It's free and no payment details are required
For membership options and pricing. Click here
Back to top